Li Qianwei, Liu Huan, Yin Geng, Xie Qibing
Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.
Department of General Practice, General Practice Medical Center, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.
Heliyon. 2024 Mar 31;10(7):e28399. doi: 10.1016/j.heliyon.2024.e28399. eCollection 2024 Apr 15.
Billions of apoptotic cells are swiftly removed from the human body daily. This clearance process is regulated by efferocytosis, an active anti-inflammatory process during which phagocytes engulf and remove apoptotic cells. However, impaired clearance of apoptotic cells is associated with the development of various autoimmune diseases, such as rheumatoid arthritis, systemic lupus erythematosus, and inflammatory bowel disease. In this review, we conducted a comprehensive search of relevant studies published from January 1, 2000, to the present, focusing on efferocytosis, autoimmune disease pathogenesis, regulatory mechanisms governing efferocytosis, and potential treatments targeting this process. Our review highlights the key molecules involved in different stages of efferocytosis-namely, the "find me," "eat me," and "engulf and digest" phases-while elucidating their relevance to autoimmune disease pathology. Furthermore, we explore the therapeutic potential of modulating efferocytosis to restore immune homeostasis and mitigate autoimmune responses. By providing theoretical underpinnings for the targeting of efferocytosis in the treatment of autoimmune diseases, this review contributes to the advancement of therapeutic strategies in this field.
人体每天会迅速清除数十亿的凋亡细胞。这一清除过程由胞葬作用调节,胞葬作用是一个活跃的抗炎过程,在此过程中吞噬细胞吞噬并清除凋亡细胞。然而,凋亡细胞清除受损与多种自身免疫性疾病的发生发展有关,如类风湿性关节炎、系统性红斑狼疮和炎症性肠病。在本综述中,我们全面检索了2000年1月1日至今发表的相关研究,重点关注胞葬作用、自身免疫性疾病发病机制、胞葬作用的调控机制以及针对这一过程的潜在治疗方法。我们的综述强调了参与胞葬作用不同阶段的关键分子,即“找到我”“吃掉我”以及“吞噬并消化”阶段,同时阐明了它们与自身免疫性疾病病理学的相关性。此外,我们探讨了调节胞葬作用以恢复免疫稳态和减轻自身免疫反应的治疗潜力。通过为在自身免疫性疾病治疗中靶向胞葬作用提供理论基础,本综述有助于推动该领域治疗策略的进步。
Front Immunol. 2018-7-20
Int Immunol. 2018-11-14
Nat Rev Drug Discov. 2022-8
Front Cell Dev Biol. 2024-1-8
Pharmacol Ther. 2022-1
Immunol Rev. 2023-10
Explor Target Antitumor Ther. 2025-4-10
Clin Rev Allergy Immunol. 2025-2-11
ACS Chem Biol. 2025-2-21
Cell Death Discov. 2024-12-18
Front Immunol. 2024
Int Immunopharmacol. 2023-3
Arthritis Rheumatol. 2023-5